Bristol-Myers to Acquire Amira Pharma For $325 Million

Bristol-Myers Squibb said Thursday it has agreed to acquire Amira Pharmaceuticals, a privately held company, for an upfront payment of $325 million in cash.

The terms also include a potential additional milestone payments totaling $150 million. The closing of the transaction is subject to customary regulatory approvals.

Amira, a small-molecule pharmaceutical company, focuses on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

By lapping up Amira, Bristol-Myers Squibb said it will have access to Amira's fibrosis program, including its lead asset AM152, an orally available lysophosphatidic acid 1 receptor antagonist which has completed Phase I studies for treatment of idiopathic pulmonary fibrosis and systemic sclerosis, or scleroderma. The program is now poised for phase 2a studies.

Bristol-Myers Squibb will also obtain Amira's preclinical autotaxin program, which may be useful in the treatment of neuropathic pain and cancer metastases.

Bristol-Myers Squibb said it plans to retain Amira Pharmaceuticals' scientists who work on both of these programs and they will remain located in San Diego.

 

Artificial Intelligence

Pierre Racz: "Real Artificial Intelligence Does Not Exist"
part one of a three-part interview series

Pierre Racz: "Real Artificial Intelligence Does Not Exist"

In part one Pierre Racz, President of Genetec, is addressing why IP network video systems were the game changer in the industry and why he does not like the term AI.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
24.01.2025 • News

CEFIC Publishes 2024 Facts and Figures Report

CEFIC , the European Chemical Industry Council, has published its 2024 Facts & Figures report, which reinforces the need to take bold and urgent action to secure Europe’s industrial future, not only to implement the Green Deal but also to prevent further de-industrialization in Europe.

Photo
24.03.2025 • News

Coco Custo – Clean Clothes, Cleaner Ingredients, Clean Sea

The Indian, woman-led startup Coco Custo is pioneering more sustainable cleaning solutions with its biodegradable laundry detergent and other eco-friendly cleaning powders. Formulated primarily from plant-based ingredients and minerals, including organic oils and coconut, Coco Custo’s products are non-toxic, hypoallergenic, and free from harmful chemicals.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.